Najim Omar, Papadimitriou Konstantinos, Broeckx Glenn, Huizing Manon, Tjalma Wiebren
Multidisciplinary Breast Clinic Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
Faculty of Medicine, University of Antwerp, Edegem, Belgium.
Front Oncol. 2023 Aug 22;13:1221773. doi: 10.3389/fonc.2023.1221773. eCollection 2023.
Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.
多项回顾性和前瞻性研究表明，雌激素受体1（ESR1）的基因组改变不仅可以在组织样本中得到表征，还可以通过对液体活检中的循环肿瘤DNA（ctDNA）进行测序来表征。因此，液体活检是组织活检潜在的非侵入性替代方法。本荟萃分析旨在比较液体活检和组织活检检测到的ESR1突变的发生率。对2007年1月1日至2021年3月1日期间发表的关于ESR1突变分析方法的研究进行了汇总荟萃分析。液体活检是一种有效、廉价且有吸引力的非侵入性替代肿瘤活检方法，用于识别ESR1突变。用于ESR1分析的液体活检将有助于定期检测，从而监测对内分泌治疗（ET）的敏感性并指导治疗策略。
